The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Merck & Co Inc

NYSE: MRK
Last

(U.S.) $59.75

Today's change+0.41 +0.69%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Merck & Co Inc

NYSE: MRK
Last

(U.S.) $59.75

Today's change+0.41 +0.69%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Merck & Co Inc up (U.S.)$0.41

Merck & Co Inc closed up Wednesday by (U.S.)$0.41 or 0.69% to (U.S.)$59.75. Over the last five days, shares are unchanged, but are currently 2.58% below its 52-week high. This security has outperformed the S&P 500 by 5.53% during the last year.

Key company metrics

  • Open(U.S.) $59.70
  • Previous close(U.S.) $59.34
  • High(U.S.) $59.77
  • Low(U.S.) $59.35
  • Bid / Ask(U.S.) $59.68 / (U.S.) $59.80
  • YTD % change+19.38%
  • Volume6,280,577
  • Average volume (10-day)8,237,700
  • Average volume (1-month)11,122,465
  • Average volume (3-month)10,659,368
  • 52-week range(U.S.) $47.61 to (U.S.) $61.33
  • Beta0.33
  • Trailing P/E32.75×
  • P/E 1 year forward17.01×
  • Forward PEG2.68×
  • Indicated annual dividend(U.S.) $1.76
  • Dividend yield2.95%
  • Trailing EPS(U.S.) $1.82
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+12.59%

Based on its net profit margin of 12.59%, Merck & Co Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.23%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue10,55710,93410,26411,320
Total other revenue--------
Total revenue10,55710,93410,26411,320
Gross profit6,4216,2126,3616,713
Total cost of revenue4,1364,7223,9034,607
Total operating expense9,2339,6938,3369,991
Selling / general / administrative2,7972,8972,7342,982
Research & development1,4841,6211,5741,837
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)816453125565
Other operating expenses, total--------
Operating income1,3241,2411,9281,329
Interest income (expense), net non-operating-191-188---201
Gain (loss) on sale of assets--------
Other--------
Income before tax1,4901,8912,0911,225
Income after tax8422,0331,731815
Income tax, total648-142360410
Net income8952,0041,705781
Total adjustments to net income------0
Net income before extra. items8952,0041,705781
Minority interest53-29-26-34
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items8952,0041,705781
Inc. avail. to common incl. extra. items8952,0041,705781
Diluted net income8952,0041,705781
Dilution adjustment0000
Diluted weighted average shares2,9112,9492,9712,963
Diluted EPS excluding extraordinary itemsvalue per share0.310.680.570.26
Dividends per sharevalue per share0.440.440.440.43
Diluted normalized EPSvalue per share0.470.780.610.39